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Abstract Background In ulcerative colitis (UC), a
state of hypercoagulation has frequently been observed.
Low molecular weight heparin (LMWH) has shown
beneficial effects as an adjuvant treatment of steroid
refractory UC in open trials. We assessed potential
therapeutic effects of the LMWH reviparin in hospita-
lised patients with mesalazine refractory UC, as well as
its influence on haemostasis factors. Methods Twenty-
nine patients with mild-to-moderately active UC were
included in a double-blind placebo controlled trial. All
patients had a flare-up of disease under mesalazine
treatment. Reviparin (Clivarin) 3,436 IU anti-Xa/0.6
ml or placebo s.c. was added, and self-administered twice
daily for 8 weeks. Patients were monitored for possible
adverse events and changes in clinical symptoms.
Endoscopical, histological, biochemical and haemosta-
sis parameters were analysed.
Results Tolerability and compliance were excellent
and no serious adverse events occurred. No significant
differences were observed on the clinical, endoscop-
ical and histological outcome, as compared to pla-
cebo. A high intrinsic and extrinsic thrombin potential
was found before LMWH therapy. However, the
significant reduction in the thrombin generation by
LMWH was not related to the reduction in disease
activity.
Conclusion The LMWH reviparine reduces throm-
bin generation in patients with mild-to-moderately
active, mesalazine refractory UC, but is not associated
with a reduction in disease activity.
Keywords Low molecular weight heparin 
Reviparin  Thrombin  Ulcerative colitis
Introduction
In inflammatory bowel disease (IBD), histologic and
systemic signs of enhanced coagulation are well doc-
umented [1–9], and an increased risk of thrombo-
embolic complications is well recognised in patients
with ulcerative colitis (UC) and Crohn’s disease (CD)
[10–13]. The use of anticoagulants like low molecular
weight heparin (LMWH) seems paradoxical as a
therapy for a disorder characterised by bleeding.
However, ‘‘fibrinoid’’ mucosal capillary thrombi have
been detected in rectal biopsies of patients with UC
[14]. As the micro-vascular thrombi were found with-
out a clear relationship to the degree of surrounding
inflammation, they might represent an association with
underlying pathophysiological mechanisms [14, 15].
The finding of raised levels of plasma coagulation and
fibrinolysis end-products indirectly reflects a state of
hypercoagulation in patients with IBD [16].
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More direct thrombin activity is difficult to measure,
as it is a transient phenomenon during the clotting
process. Currently, thrombin activity can be quantified
by measuring the amount of product that is produced
from an artificial thrombin substrate during coagula-
tion. The time course of the thrombin generation curve
reflects the function of the ensemble of plasmatic pro-
and anticoagulant factors in platelet-poor plasma
(PPP), as well as the procoagulant role of platelets in
platelet-rich plasma (PRP) [17]. Both the extrinsic and
intrinsic thrombin potential (ETP and ITP) seems to
be increased in other thrombosis-prone states investi-
gated [18, 19], but in IBD patients, the level of
thrombin generation has not been reported before.
As LMWH therapy may produce a benefit by affecting
micro-vascular thrombi in the gut [20, 21], its admin-
istration could be rational in patients with UC or CD-
resistant to conventional forms of treatment.
The aim of this study was to clarify whether an
improvement of clinical disease activity after LMWH
therapy was associated with a reduced thrombin
generation in patients with mild-to-moderately active
UC, unresponsive to mesalazine. We additionally
investigated the relationship of thrombin generation
with other haemostasis factors in these patients.
Methods
Patients
In a prospective randomised double-blind placebo
controlled trial, 29 patients with mild-to-moderately
active mesalazine refractory UC were seen at the
University Hospitals of Maastricht and Groningen,
The Netherlands, and enrolled in this study from
August 1996 to February 2000. The diagnosis UC was
based on the Lennard-Jones criteria [22], and patients
with a severity score of 4–14 according to the modified
Truelove classification [23], were eligible. The active
colitis could either be the first manifestation or an
exacerbation of the disease. Sigmoidoscopy had to be
performed less than 2 weeks before start of treatment.
Excluded from the trial were patients with proven CD,
infectious colitis, ischaemic colitis or irradiation colitis.
Use of oral or rectal corticosteroids or other immuno-
suppressive drugs was prohibited within 4 weeks before
study entry. Also excluded were patients with known
thrombo-embolic disposition or current use of antico-
agulants, patients with known or suspected general
bleeding tendency, and patients with regular use of
non-steroidal anti-inflammatory drugs or aminosalicy-
lates. Previous adverse events to heparin therapy,
known active ulcer disease, serious hepatic disease
(ASAT > 3· upper limit) or renal failure (serum
creatinin > 300 lmol/l), as well as pregnancy or breast-
feeding in female patients, were other exclusion
criteria. Written informed consent was obtained from
all patients. The ethical committees of both participat-
ing hospitals approved the protocol.
Study design
After randomisation (random allocation), the patients
received either reviparin (Clivarin) 3,436 IU Pharm
Eur/0.6 ml (corresponding to 10,000 U of unfraction-
ated calcium heparin) or placebo subcutaneously twice
daily.
The drug and placebo were made available in
individually packed disposable syringes. Both were
administered through self-injection. All patients were
on stable treatment with either salazopyrine (n = 4) or
mesalazine (n = 20) 1 g 2–3 times daily or olsalazine
(n = 5) in a comparable dose.
Clinical disease activity was determined by the
Colitis Activity Index (CAI) [24] (from 0 to 21; severe
disease defined as > 12, inactive disease < 4) on week 0
or just before treatment, and after 1, 2, 4, 6 and 8 weeks
of treatment. Quality of life was assessed at week 1, 4
and 8 by means of the Inflammatory Bowel Disease
Questionnaire (IBDQ) [25].
The endoscopic severity of disease was scored by
means of the Endoscopic Grading System [26] or EGS
(from 0 to 26; severe disease >18) within 2 weeks prior
to LMWH treatment. Also, a grading of histologic
disease activity (HDA, from 0 to 12; severe inflamma-
tion >10) was performed [26]. Duplicate biopsies
(3 mm) were taken from the most severely affected
area, at 10 cm from the anus in the rectum and at 25 cm
in the sigmoid. The recording of endoscopic and
histological scores was done with reference to the
most inflamed site in the colon or rectum. The EGS
and HDA score were repeated after 8 weeks of
treatment, and one experienced pathologist assessed
all biopsies in a blinded manner.
At regular intervals (week 0 or just before treat-
ment, and after 1, 2, 4, 6 and 8 weeks of treatment),
laboratory tests were performed: the erythrocyte sed-
imentation rate, red and white blood cell counts,
platelet counts (normal values: 130–350 · 109/l), mean
platelet volume (MPV; 8.6–9.7 fl), platelet distribution
width (PDW; 15–18%), serum levels of C-reactive
protein (CRP; 0–9 mg/l), alkaline phosphatase (AP;
30–125 IU/l), gamma-glutamyl-transpeptidase (GGT;
10–50 IU/l), lactate dehydrogenase (100–250 IU/l), and
serum levels of aspartate aminotransferase (AST; 5–40
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IU/l) and alanine aminotransferase (ALT; 5–40 IU/l)
and creatinin (creat; 40–90 lmol/l).
Different markers of coagulation like the APTT (24–
35 s, thrombin–antithrombin complex (TAT; 0.00–1.90
lg/ml), prothrombin fragment 1 and 2 (F1.2; 0.40–1.45
nmol/l), as well as anti-IIa activity (0.0–0.07 U/ml), anti-
Xa activity (0.0–0.02 U/ml) and the ITP and ETP were
determined. Treatment was intended to last 8 weeks.
Control visits were planned at 1, 2, 4, 6 and 8 weeks.
Treatment was discontinued if there was no
improvement after 4 weeks according to the CAI
[24], or in any patient with progression of disease
activity at any control visit. Other predefined reasons
for discontinuation were heparin-induced thrombocy-
topenia (HIT) type 2 [27, 28] and/or severe bleeding
(defined as Hb < 5.0 mmol/l, Hb > 2.0 mmol/l below
baseline value, blood loss with blood pressure <80/50
mmHg and/or need for blood transfusion). In patients
in whom the study treatment was discontinued, a
treatment with corticosteroids was initiated.
Preparation of plasma
The collection of blood was strictly timed, i.e. 30 min
before the next dose of LMWH in the morning, and 30
min before laboratory analysis started.
Fresh citrated blood (nine parts of blood to one part
of 0.13 mol/1 trisodiumcitrate) was centrifuged at 250g,
15C for 10 min. The platelet count was adjusted to 3 ·
108/ml using autologous PPP, made by double centri-
fugation of PRP at 1,000g, 15C for 10 min. Before
storage at –80C, PPP was centrifuged twice at l,000g
for 10 min. Plasma was defibrinated by adding 1/50
volume of Ancrod and clot dissolution. After the
thrombin generation test had been performed, the
remaining serum was put on ice and centrifuged at
15,000g for 2 min. The supernatant was stored at –80C.
Normal pool plasma was pooled PPP from at least ten
apparently healthy male and female donors and stored
at –80C for less than 4 months.
Measurement of thrombin generation
Thrombin generation was measured with a subsam-
pling technique, as previously described in detail [17–
19], either triggered by tissue factor (extrinsically) or
by contact activation (intrinsically). In short, thrombin
was determined by monitoring optical density of the
pNA at 405 nm, released from a slow-reacting chro-
mogenic thrombin substrate (DEMZ-Gly-Arg-pNA)
which was added to the defibrinated plasma upon
recalcification. The reacting mixture for the measure-
ment of thrombin generation consisted of one part of
buffer containing phospholipid vesicles (20 mol%
phosphatidylserine and 80 mol% phosphatidylcholine).
For the extrinsic system, 4 lM phospholipid with 15
pM recombinant human tissue factor was added, and
for the intrinsic system 4 lM phospholipid and 1/6
volume of Actin-FSL (Dade Behring). The ETP and
ITP level is expressed as a percentage of the ETP and
ITP of normal pool plasma, measured simultaneously.
The mean value of ETP in PPP in healthy controls was
737 nmol/l min (range 720–790), the mean ITP level in
PPP in healthy controls was 798 nmol/l min (range
780–850) [29, 30]. The normal values of ETP, ITP, as
well as TAT and F1.2, were obtained from ten healthy
controls (five male, five female), and were compared
with the values of the patients.
Statistical analysis
The sample size of the clinical trial was based on
categorical data (‘‘did the patient improve?’’). For the
expected proportion with specified outcome was cho-
sen: p1 = improved on LMWH 0.80, p2 = improved on
placebo 0.20. The calculated SD was 1.2. Taking the
power to be 0.85 and a one-sided significance level of
0.05, the sample size was calculated to be 24 for each
group. Analysis was performed on an intention-to-treat
basis with last value carried forward in case of
premature discontinuation. To test differences for
significance, the Mann–Whitney–Wilcoxon rank–sum
test was performed. A Bonferroni adjustment was used
for multiple comparisons, and an alpha level of 0.017
was considered significant with tests performed at 0, 4
and 8 weeks [31]. Also, the Spearman rank correlation
coefficient and the two-tailed significance of the
correlation were calculated between the coagulation
factors and other biochemical and disease parameters.
SPSS 13.0 software (SPSS Inc., USA) was used for
statistical analysis.
Results
Patients
Fifteen patients were randomised to receive the
LMWH reviparin and 14 to receive placebo (19
patients were studied in the University Hospital
Maastricht and 10 in the University Hospital Gronin-
gen). Demographic data and clinical characteristics of
patients randomised to treatment are shown in
Table 1. There was no difference between the two
groups with regard to age, gender, smoking habits or
disease severity as measured by CAI. Mean duration
123
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and extent of disease, previous steroid treatment and
individual or family history of thrombosis or bleeding
tendency were similar in both groups.
Influence of additional LMWH treatment
on the CAI, IBDQ, EGS and HDA
In the reviparin group 11/15 (73.3%) patients com-
pleted the 8 weeks of treatment, in the placebo group
9/14 (64.3%; p = 0.70). One patient in the placebo
group was lost to follow-up after 2 weeks. In all other
patients, reason for discontinuation was either lack of
efficacy or exacerbation. At 8 weeks the improvement
in CAI was 3.80 points in the reviparin group and 2.08
points in the patients treated with placebo (p = 0.20).
In the reviparin group 12/15 (80%) patients had
improved, compared to 11/13 (85%) in the placebo
group (p = 1.0).
There were no significant differences in IBDQ,
ESG, or HDA between both groups (Table 2).
Haemostasis characteristics and the influence
of LMWH treatment on thrombin generation,
haemostasis and fibrinolysis factors at baseline,
at 4 and at 8 weeks
At baseline, patients in the LMWH group had above
normal levels of ETP (777; 171) and ITP (824; 188)
(p = 0.02). Also, patients in the placebo group had
higher levels of ETP (784; SD 87) and ITP (833; SD
100), than the normal control values of ETP (737; 19
with p < 0.001), and ITP (798; 19 with p < 0.01).
At baseline, TAT and F1.2 were significantly raised
in the LMWH and placebo group, compared to the
healthy controls (p < 0.0001 and p < 0.0001 respec-
tively). The APTT, the anti-IIa and the anti-Xa activity
was within normal limits in the LMWH and placebo
group.
At 4 weeks, the ETP and ITP values were signifi-
cantly lower in the LMWH-treated group, as compared
to the placebo group (p = 0.014 and 0.015), as well as
the healthy controls (p = 0.001 and 0.001). However,
TAT and F1.2 levels were higher, both in the LMWH
group (p < 0.0001 and p = 0.004) and placebo group
(p < 0.0001 and p = 0.004), as compared to the healthy
controls. Also, anti-IIa (p < 0.0001) and anti-Xa
activity (p < 0.0001), as well as APTT (p = 0.007)
and ALT levels (p = 0.008), were significantly higher in
the LMWH-treated patients, as compared to placebo.
At 8 weeks, the ETP and ITP values were not
significantly lower in the LMWH-treated group, as
compared to the placebo group (p = 0.536 and 0.887), or
the healthy controls (p = 0.238 and p = 0.892). However,
TAT (p < 0.0001) and F1.2 (p = 0.039) were higher in
the placebo group, as well as was TAT in the LMWH
group (p < 0.0001), as compared to the healthy controls.
Also, the anti-Xa activity, but not the anti-IIa,
APTT or ALAT levels, was significantly higher at 8
weeks in the LMWH-treated patients, as compared to
placebo (p = 0.002). Table 3 summarises the differ-
ences of laboratory data between the reviparin and
placebo-treated groups. The time course of ETP and
ITP is shown in Figs. 1 (reviparin) and 2 (placebo). The
time course of TAT and F1.2 is shown in Figs. 3
(reviparin) and 4 (placebo). The box-whisker plots
represent the median (line between the 25th and 75th
percentile box) and min–max values (whisker lines
extended from the box as smallest and largest values),
as well as outliers (0) and extremes (*).
Table 1 Baseline characteristics of placebo and reviparin-trea-
ted patients
Placebo Reviparin Significance
Number of patients 14 15 ns
Age (mean) 42 38 ns
Sex (M/F) 7/7 9/6 ns
Smoking (previous/never) 1 (11/2) 3 (8/4) ns
Previous steroid use 9 9 ns
CAI (min–max) 9 (3–13) 10 (5–16) ns
Duration of disease
in years (range)
7 (0–26) 6 (0–15) ns
ns not significant
Table 2 Clinical (CAI, IBDQ), endoscopical (EGS) and histological (HDA) activity indices, before and after reviparin therapy or
placebo, are shown
Placebo Reviparin
Week 0 Week 4 Week 8 Week 0 Week 4 Week 8
CAI 9.1 [3.1] 7.3 [3.2] 5.8 [3.1] 9.9 [2.9] 6.7 [3.5] 5.1 [3.5]
IBDQ 147 [24] 154 [25] 167 [23] 133 [30] 159 [38] 169 [44]
EGS 9.5 [3.3] Not done 7.3 [5.3] 9.6 [3.2] Not done 7.4 [4.3]
HDA 3.9 [2.1] Not done 3.1 [2.5] 2.9 [1.8] Not done 2.0 [2.2]
Means and standard deviations ([ ]) between the groups with reviparin and those with placebo are presented at week 0, 4 and 8. No
significant differences were found between these groups
123
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Relationship between haemostasis parameters
and CAI, CRP, endoscopic and histologic
parameters
In the placebo-treated patients, the clinical activity score
CAI was positively correlated with the ITP (r = 0.267;
p = 0.038), as well as platelet count (r = 0.506; p <
0.0001) and APTT (r = 0.336; p = 0.007), and inversely
correlated to PDW (r = –0.552; Spearman’s rho, two-
tailed significance p < 0.0001). CRP correlated positively
with ETP (r = 0.531; p < 0.0001), ITP (r = 0.664; p <
0.0001) and anti-Xa (0.336; p = 0.007), and inversely
with MPV (r = –0.361; p = 0.002) and PDW (r = –0.382;
p = 0.018). The endoscopy and histology score EGS and
HDA did not correlate with the haemostasis parameters
in the placebo group.
In the LMWH-treated group, CAI correlated
inversely with MPV (r = –0.293; p=0.008), and inver-
sely with the APTT (r = –0.271; p = 0.016). CRP
correlated with platelet count (r = 0.344; p = 0.001),
ETP (r = 0.472; p < 0.0001), ITP (r = 0.491; p < 0.0001),
TAT (r = 0.283; p = 0.014) and APTT (r = 0.315;
p = 0.004). The EGS did not correlate with ETP, and
the HDA correlated inversely with ETP (r = –0.456;
p = 0.029).
Table 3 Laboratory data with means, standard deviations ([ ]) and significant differences (*p < 0.017) between the groups treated with
reviparin or placebo, at weeks 0, 4 and 8
Placebo Reviparin
Week 0 Week 4 Week 8 Week 0 Week 4 Week 8
Biochemistry
CRP (mg/l) 11.4 [16.2] 11.2 [12.0] 18.9 [19.5] 16.0 [18.2] 10.4 [13.0] 20.8 [36.8]
Albumin (g/l) 40.3 [5.4] 40.5 [4.7] 40.7 [4.2] 40.3 [4.6] 41.3 [6.5] 41.4 [3.6]
ALT (IU/l) 18.6 [6.2] 20.0 [6.4] 18.0 [6.5] 26.1 [26.2] 35.3 [18.9]* 24.8 [13.2]
Platelets
Number (109/l) 276 [60] 280 [81] 285 [77] 275 [66] 274 [65] 286 [71]
MPV (fl) 8.0 [0.9] 7.9 [0.7] 7.8 [1.1] 7.7 [1.0] 7.8 [0.6] 7.8 [0.6]
PDW (%) 16.4 [0.7] 16.5 [0.3] 16.6 [0.3] 16.5 [0.5] 16.3 [0.6] 16.5 [0.3]
Coagulation
APTT (s) 31.4 [3.9] 30.6 [3.0] 31.7 [4.4] 32.7 [4.5] 35.3 [4.7]* 36.3 [5.2]
TAT (lg/ml) 3.61 [2.19] 5.23 [8.29] 2.63 [0.65] 6.73 [9.09] 7.44 [17.13] 2.47 [1.48]
F1.2 (nmol/l) 1.29 [0.45] 1.53 [0.62] 1.40 [0.45] 2.26 [2.40] 1.92 [2.12] 1.29 [0.52]
ETP (nmol/l min) 784 [87] 743 [115] 767 [73] 777 [171] 598 [172]* 722 [183]
ITP (nmol/l min) 833 [100] 815 [99] 782 [79] 824 [188] 613 [211]* 793 [256]
Anti-IIa (U/ml) 0.043 [0.034] 0.053 [0.038] 0.064 [0.025] 0.038 [0.023] 0.135 [0.057]* 0.095 [0.052]
Anti-Xa (U/ml) 0.006 [0.009] 0.008 [0.006] 0.007 [0.005] 0.013 [0.019] 0.552 [0.173]* 0.334 [0.271]*
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Fig. 1 Box-whisker plots of ETP and ITP (nmol/l min; normal
mean values of ETP and ITP are 737 and 798), during 8 weeks of
follow-up in patients with UC, treated with mesalazine and
reviparin
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Fig. 2 Box-whisker plots of ETP and ITP (nmol/l min; normal
mean values of ETP and ITP are 737 and 798), during 8 weeks of
follow-up in patients with UC, treated with mesalazine and
placebo
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Discussion
To our knowledge, this is the first study to present data
on direct thrombin generation in patients with UC. The
study demonstrates that the thrombin potential, both
intrinsic and extrinsic, is above the norm in patients
with active UC, confirming more indirect data on
hypercoagulation in these patients [16]. The adminis-
tration of LMWH diminished the ITP and ETP in
patients with UC, comparative to the effect of LMWH
on patients with active thrombo-embolic diseases
[18, 30, 32].
In the reviparin-treated group, the anti-IIa activity
and APTT were raised after 4 weeks of treatment.
However, both normalised after 8 weeks, while the
anti-Xa activity was still raised. Although we did not
find a clear explanation for the gradual loss of anti-IIa
activity in our patients, a more selective LMWH anti-
Xa activity was expected from literature [20]. Surpris-
ingly, the administration of a therapeutic dose of
reviparin was accompanied by a rise in the thrombin
potential at week 8, not different from baseline levels.
On the one hand, this questions the effectiveness of
selective anti-Xa blocking agents on reducing the
thrombin potential over time in patients with UC.
The size of the effect on thrombin generation might
depend on the type of activation used to initiate the
clotting, which could be dependent of higher amounts
of tissue factor [33].
On the other hand, the scheduled dose of reviparin
(3,436 IU/12 h) corresponds to 10,000 IU/12 h of
unfractionated heparin, and this might be considered
as an intermediate dose.
We do not know if a higher dose (e.d. 15,000 IU/
12h) would be effective in improving the clinical
outcomes of UC, as the reached anti-Xa plasma level
at 8 weeks was below the generally accepted thera-
peutic range of 0.4–1.0 aXa IU/ml.
No correlation was found between the (level of)
reduction of the thrombin potential and both clinical
(CAI; IBDQ), endoscopy and histology scores. How-
ever, a positive correlation was found between ETP
and ITP with CRP, suggesting a pattern of acute phase
reactivity in thrombin generation. The more stable
end-products F1.2 and TAT did not correlate with CAI
and CRP in the placebo-treated patients and this might
favour the use of ITP or ETP as indices of UC disease
activity over that of F1.2 and TAT.
No additional benefit of reviparin was found com-
pared to the placebo-treated patients, on CAI, IBDQ,
EGS and HDA. This is in contrast with the positive
results found in a previous but open study done with
nadroparin, in corticosteroid-resistant UC patients
[15]. It suggests that LMWH, in combination with
aminosalicylates but in the absence of corticosteroids,
does not have any therapeutic advantage above a
placebo, as was recently also shown by other investi-
gators [34].
A masking effect due to the use of aminosalicylate
therapy remains possible, although 8 weeks of therapy
should have led to induction of remission. Also, the
8-week observation period following LMWH and
placebo might have been too short to evaluate if a
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Fig. 4 Box-whisker plots of TAT (lg/ml; normal upper limit 1.90
lg/ml) and F1.2 (nmol/l; normal upper limit 1.45 nmol/l) during 8
weeks of follow-up in patients with UC, treated with mesalazine
and placebo
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Fig. 3 Box-whisker plots of TAT (lg/ml; normal upper limit 1.90
lg/ml) and F1.2 (nmol/l; normal upper limit 1.45 nmol/l) during 8
weeks of follow-up in patients with UC, treated with mesalazine
and reviparin
123
J Thromb Thrombolysis
reduced thrombin generation has any influence with
respect to the HDA score. However, the combination
of LMWH and corticosteroids did reduce the HDA
score significantly within 8 weeks of therapy in a
previous study [15].
Regrettably, the number of subjects needed to reach
statistical power was not met in this study, because of
slow recruitment.
Also, the placebo response in this patient group was
above 60%, and was much higher than the 20% antici-
pated. These factors may have contributed to lacking
evidence for benefit of LMWH treatment on clinical,
endoscopy and histology outcomes in patients with mild-
to-moderately active UC.
Also, patients with known arterial or venous throm-
bo-embolic complications were excluded to overcome
the bias of having an underlying tendency of hyperco-
agulation, unrelated to UC. However, data from open
trials showed that LMWH therapy can reduce colitis
activity in patients with active thrombosis, and these
could have been patients to most benefit from LMWH
treatment.
To prevent thrombo-embolic complications frequently
seen in patients with UC, the use of an LMWH seems
logical, as it reduces the state of hypercoagulation as was
present in our patients at baseline. A higher dose of
reviparin could be necessary to effectively reduce the
thrombin potential in these patients over time periods
longer than 4 weeks. This phenomenon of therapeutic
‘‘resistance,’’ or possibly tachyphylaxis, needs further
investigation.
With the reviparin doses used we observed a
temporary rise in the liver ALT level, a known side
effect of heparin treatment [35], also reported in a
previous study on LMWH in UC [15]. Fortunately, as
in other studies [15, 34], no serious bleeding compli-
cations were encountered, suggesting that LMWH is a
relatively safe drug in this patient group with tendency
for mucosal bleeding.
In conclusion, in patients with mild to moderate UC,
the addition of the LMWH reviparin to mesalazine did
not change clinical outcome; it reduces the thrombin
potential and might therefore prevent thrombo-em-
bolic complications in these patients.
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